Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 23, 2022
Data Byte

Translational spotlight on East-West innovation 

Collaborations between investigators at Asian and Western universities in BioCentury’s Distillery present licensing and partnering opportunities
BioCentury | Oct 7, 2022
Distillery Therapeutics

Overexpressing ANXA2 or MPP1 for glaucoma

BioCentury | Jul 29, 2021
Distillery Therapeutics

PTEN mRNA nanoparticles increase sensitivity to cancer immunotherapy

DISEASE CATEGORY: Cancer
INDICATION: Melanoma; prostate cancer Restoring the expression of the tumor suppressor PTEN via nanoparticle delivery of PTEN mRNA could enhance the efficacy of
BioCentury | Apr 22, 2019
Distillery Therapeutics

The former diabetes drug phenformin for T cell ALL

BioCentury | Jan 4, 2019
Tools & Techniques

Making AD mice as diverse as patients

How adding genetic diversity to Alzheimer’s mice could help define responders
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

BioCentury | Oct 31, 2018
Distillery Therapeutics

Cancer

Items per page:
1 - 10 of 120